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Use of a Smartwatch for Assessment of the
QT Interval in Outpatients with Coronavirus
Disease 2019
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SAMY SELIM, md,1 and LAURENCE M. EPSTEIN, md1
Southside Hospital, Northwell Health Physician Partners, Zucker School of Medicine at Hofstra/Northwell,
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ABSTRACT. The coronavirus disease 2019 (COVID-19) pandemic has necessitated rapid
implementation of innovative strategies to manage patients remotely to help reduce the risk of
community and nosocomial transmission. This case demonstrates the use of an Apple Watch
(Apple, Cupertino, CA, USA) to monitor for arrhythmias and QT prolongation in a patient with
COVID-19 during home isolation.
KEYWORDS. Coronavirus, COVID-19, smartwatch, QT prolongation, wearable cardiac
monitor.

Introduction
During the ongoing coronavirus disease 2019 (COVID19) pandemic, limitations in health care resources and the
introduction of extensive protections against viral dissemination have forced the development and adoption of
novel approaches to support previously routine patient
management. Patients with COVID-19 infection are at risk
for various cardiovascular and arrhythmic complications.1
In addition, medications being explored to treat COVID19 infection, such as chloroquine, hydroxychloroquine,
and azithromycin, carry a risk of cardiac complications,
particularly a dose-dependent risk of QT prolongation
and ventricular arrhythmia.2,3 In hospitalized patients,
QT monitoring during the course of treatment with these
medications may be performed using serial electrocardiograms (ECGs), telemetry, or even ambulatory telemetry monitors.4 However, the limited availability of such
resources due to high demand alongside the precautions
set in place to protect health care providers from contact
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with contagious patients has precluded standard monitoring techniques. Furthermore, most patients with COVID19 infection are treated as outpatients, employing self-isolation to reduce the risk of nosocomial and community
spread.5 A sudden and dramatic increased reliance on
telehealth and remote ECG monitoring to manage these
patients at home has therefore emerged.
Wearable and “smart” cardiac monitoring devices such
as the Apple Watch series 4 (Apple, Cupertino, CA, USA)
and the AliveCor Kardia system (AliveCor Inc., San Francisco, CA, USA) have the ability to record a rhythm strip
essentially equivalent to lead I on a standard ECG and
deliver the results via electronic transmission. While
these devices have been validated for their ability to monitor heart rates and differentiate sinus rhythm from atrial
fibrillation,6 their accuracy for other ECG-interpretation
purposes has not been well studied to date. However, the
waveforms produced have been shown to correlate reasonably well with standard ECG intervals including the
corrected QT (QTc) interval7 and have previously been
used to detect drug-induced QT interval prolongation.8
As patients with COVID-19 infection continue to overwhelm our global health care system and resources,
the ability to remotely monitor patients for cardiac
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complications of COVID-19 infection and ensure their
safety during pharmacologic treatment has become
increasingly important. Currently available wearable cardiac monitoring devices may therefore play an important
role in the management of patients in this pandemic.

which confirmed the waveform measurements obtained
by the Apple Watch (QTc interval was 457 ms on ECG)
and demonstrated consistency between limb lead measurements (QT interval was 380 ms in both leads I and II).

We report herein a case of a patient with COVID-19 infection who was treated with a QT-prolonging medication
and was able to be managed remotely with the assistance
of a smartwatch device.

Discussion

Case presentation
A 40-year-old female physician with no prior cardiac history presented with fevers, chills, cough, and dyspnea.
Due to known exposures to patients and close relatives
with confirmed COVID-19 infection, she was immediately placed in home isolation and managed by her primary care provider and cardiologist using telemedicine.
Due to persistent fevers, she was prescribed hydroxychloroquine (400 mg twice daily for one day and then
200 mg twice daily for four days to complete a five-day
course). No baseline ECG was available; however, she
was considered to be at moderate risk for drug-associated QT prolongation due to a Tisdale risk score of seven
points.9 As such, she used her Apple Watch to record
rhythm strips approximately two to three hours after
each dose of hydroxychloroquine administration and
transmitted these results to her cardiologist (Figure 1).
Her QTc interval was 441 ms at baseline (measured using
Bazett’s correction), increased to 476 ms after the third
dose, and then returned to baseline at 440 ms one day
after the completion of the five-day course. No arrhythmias were detected during the course of treatment by
the Apple Watch. She was able to complete treatment at
home and, as her symptoms improved, a 12-lead ECG
was subsequently performed in the hospital (Figure 2),

Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the virus behind COVID-19, has a high rate of
transmission in the community as well as within health
care facilities, forcing a new emphasis to be placed on the
use of telemedicine and remote monitoring. While telehealth has previously been effective in managing patients,
in this context, performing necessary prior steps, including ECGs and the application of mobile cardiac telemetry
monitors, is precluded. At the same time, findings of cardiac complications related to SARS-CoV-2 infection and
the potential cardiac toxicity associated with common
pharmacologic treatments have prompted an increased
need for easily accessible cardiac monitoring modalities
that do not rely on physical contact with or the patient’s
presentation to a health care facility. Remote patient management using smart device–based electrocardiography
is therefore a valuable alternative to previously standard
monitoring modalities.
The waveforms provided by smart device–based ECGs
have not been vigorously assessed for the purpose of
QT measurement and no outcomes studies based on this
strategy have been conducted to date. The rhythm strip
obtained by such devices is typically derived from the
same vector as lead I of a standard 12-lead ECG; the waveforms are overlaid on standard ECG grids with recordings
at 25 mm/s and 10 mm/mV, allowing QT and RR interval measurements to be determined in milliseconds. The
QTc interval can therefore be derived in the same manner
as that adopted when using a standard 12-lead ECG. A

Figure 1: Rhythm strips used for QTc measurement. These rhythm strips were obtained from the patient’s Apple Watch during
the course of treatment. The QT and RR intervals are measured as shown and the QTc interval was calculated using Bazett’s
formula.
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with standard deviation of 11 ms as compared with the
12-lead ECG.8 Elsewhere, another study found that QTc
measurement using a single-lead handheld mobile device
is feasible, but the QTc measurement was underestimated
(23 ms; 95% confidence interval: 13–34 ms) when only a
lead I rhythm strip was obtained; when a vector analogous to lead II could be recorded, QTc measurements had
a very close correlation with the maximum QTc interval
determined by 12-lead ECG.10 Importantly, the change in
QTc during treatment with QT-prolonging medications
has also been correlated with an increased risk of torsades
de pointes,11 indicating that serial measurements collected
using a single lead (such as when using a smart device)
may provide additional value during risk stratification
even when the measured QTc value is imprecise.

A

B

C

Figure 2: A: ECG obtained following the completion of treatment under home isolation. Note the consistency in the
QT interval when measured in lead I or lead II (QT interval:
380 ms, RR interval: 690 ms, and QTc interval: 457 ms in both
leads). B: Enhancement of lead I from the 12-lead ECG. C:
Corresponding rhythm strip obtained from the Apple Watch
after treatment, where a very similar waveform morphology and QT measurements as compared with lead I on the
12-lead ECG can be noted.

recent validation study performed in 129 healthy volunteers showed a reasonable concordance between QTc
intervals measured from the Apple Watch and a 12-lead
ECG (mean difference: −11.67 ± 8.32 ms; r = 0.57).7 In
addition, a prior study demonstrated the ability to use a
smartphone-based heart monitor to accurately detect QTc
prolongation in a patient receiving QT-prolonging medications, the results of which revealed a difference of 4 ms
4221

Further validation and optimization of recording techniques are required before this technology can be promoted for routine assessment of the QT interval. If this
approach is adopted, QTc measurement can likely be
automated to improve the ease of measurement and
reduce measurement errors. The lack of multiple contiguous leads obtainable by most wearable devices limits
the sensitivity of these modalities for the detection of QT
abnormalities, which may be more pronounced in some
leads than others. While lead II is most commonly used
for QT measurement, the optimal lead for QT measurement does vary and the use of the same lead for serial
assessments is important to accurately interpret QT
changes while on medication. Lead I is frequently adequate for interpretation and the QTc measurement from
lead I has been shown to differ by an average of 7.5 ms
from that obtained from lead II.12 Various ECG vectors,
including lead II, can be obtained by both the Apple
Watch and Kardia Pro devices by repositioning the device
on the patient’s body.13 Accordingly, single-lead mobile
cardiac outpatient telemetry units have previously been
approved by the United States Federal Drug Administration for QTc measurement. Although the quality of the
electrograms produced by smart devices may be affected
by a high level of skin-to-electrode impedance, it remains
generally consistent relative to other monitoring technologies and has been well-validated for use in rhythm
interpretation.

Conclusion
Despite the above limitations, the COVID-19 pandemic
has required providers to move swiftly to use all current
resources at their disposal to both manage patients safely
and minimize the spread of infection, particularly in the
health care environment. Smart monitoring devices such
as the Apple Watch Series 4 permits monitoring of the
heart’s rhythm, rate, and QT interval and thereby can provide a distinct advantage in the management of patients
with SARS-CoV-2 infection during home isolation. This
case demonstrates one novel approach to patient management under these difficult circumstances and could
be considered further as a means to limit the risk of transmission in future outbreaks.
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